CSL Behring receives accelerated CHMP assessment for etranacogene dezaparvovec for European patients living with haemophilia B

CSL Behring

15 December 2021 - CSL Behring today announced that the CHMP, the chief scientific body of the EMA accepted its request for an accelerated assessment of the etranacogene dezaparvovec marketing authorisation application. 

Etranacogene dezaparvovec (also known as EtranaDez), currently being studied in the Phase 3 HOPE-B clinical trial, is an investigational gene therapy for people living with haemophilia B, a life-threatening bleeding disorder.

Read CSL Behring press release

Michael Wonder

Posted by:

Michael Wonder